Daniel H Bedinger
Overview
Explore the profile of Daniel H Bedinger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
317
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bedinger D, Adams S
Mol Cell Endocrinol
. 2015 Aug;
415:143-56.
PMID: 26277398
Insulin acts as the major regulator of the fasting-to-fed metabolic transition by altering substrate metabolism, promoting energy storage, and helping activate protein synthesis. In addition to its glucoregulatory and other...
2.
Bedinger D, Kieffer D, Goldfine I, Roell M, Adams S
J Cell Biochem
. 2015 Mar;
116(9):2109-19.
PMID: 25808283
It has been proposed that monoclonal antibodies may become therapeutics for metabolic diseases such as diabetes mellitus. We have previously characterized an allosteric monoclonal antibody to the human insulin receptor...
3.
Bedinger D, Goldfine I, Corbin J, Roell M, Adams S
J Pharmacol Exp Ther
. 2015 Jan;
353(1):35-43.
PMID: 25613982
The monoclonal antibody XMetA is an allosteric partial agonist of the insulin receptor (IR), which activates the metabolic Akt kinase signaling pathway while having little or no effect on the...
4.
Issafras H, Bedinger D, Corbin J, Goldfine I, Bhaskar V, White M, et al.
J Diabetes Sci Technol
. 2014 May;
8(4):865-73.
PMID: 24876415
Many therapeutic monoclonal antibodies act as antagonists to receptors by targeting and blocking the natural ligand binding site (orthosteric site). In contrast, the use of antibodies to target receptors at...
5.
Corbin J, Bhaskar V, Goldfine I, Bedinger D, Lau A, Michelson K, et al.
PLoS One
. 2014 Feb;
9(2):e88684.
PMID: 24533136
Previously we reported studies of XMetA, an agonist antibody to the insulin receptor (INSR). We have now utilized phage display to identify XMetS, a novel monoclonal antibody to the INSR....
6.
Corbin J, Bhaskar V, Goldfine I, Issafras H, Bedinger D, Lau A, et al.
MAbs
. 2014 Jan;
6(1):262-72.
PMID: 24423625
Novel therapies are needed for the treatment of hypoglycemia resulting from both endogenous and exogenous hyperinsulinema. To provide a potential new treatment option, we identified XMetD, an allosteric monoclonal antibody...
7.
Lackey D, Lynch C, Olson K, Mostaedi R, Ali M, Smith W, et al.
Am J Physiol Endocrinol Metab
. 2013 Mar;
304(11):E1175-87.
PMID: 23512805
Elevated blood branched-chain amino acids (BCAA) are often associated with insulin resistance and type 2 diabetes, which might result from a reduced cellular utilization and/or incomplete BCAA oxidation. White adipose...
8.
Schwimmer L, Huang B, Giang H, Cotter R, Chemla-Vogel D, Dy F, et al.
J Immunol Methods
. 2013 Mar;
391(1-2):60-71.
PMID: 23454004
Phage display antibody libraries have a proven track record for the discovery of therapeutic human antibodies, increasing the demand for large and diverse phage antibody libraries for the discovery of...
9.
Bhaskar V, Goldfine I, Bedinger D, Lau A, Kuan H, Gross L, et al.
Diabetes
. 2012 Mar;
61(5):1263-71.
PMID: 22403294
Many patients with diabetes mellitus (both type 1 and type 2) require therapy to maintain normal fasting glucose levels. To develop a novel treatment for these individuals, we used phage...
10.
Roell M, Issafras H, Bauer R, Michelson K, Mendoza N, Vanegas S, et al.
J Biol Chem
. 2010 Apr;
285(27):20607-14.
PMID: 20410301
Many therapeutic antibodies act as antagonists to competitively block cellular signaling pathways. We describe here an approach for the therapeutic use of monoclonal antibodies based on context-dependent attenuation to reduce...